Clinical Trial Update: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Zilovertamab Vedotin in combination with cyclophosphamide, doxorubicin, prednisone plus rituximab or a rituximab biosimilar (T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• TRUXIMA (rituximab-abbs)
• Zilovertamab vedotin (zilovertamab vedotin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Lymphoma, Large B-Cell, Diffuse (DLBCL) | Phase 2 | Status: ACTIVE_NOT_RECRUITING